Substance abuse, HIV-1 and hepatitis

Current HIV Research

Volumn 10, Issue 7, 2012, Pages 557-571

  Parikh, Nirzari ^a   Nonnemacher, Michael R ^a   Pirrone, Vanessa ^a   Block, Timothy ^a,b,c   Mehta, Anand ^a,b,c   Wigdahl, Brian ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Drexel Institute for Biotechnology and Virology   (United States)

^c BARUCH S BLUMBERG INSTITUTE   (United States)

Author keywords

Bone marrow; Brain; Cocaine; HBV; HCV; HIV 1; Opioids

Indexed keywords

CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CCR5; COCAINE; IMMUNOSUPPRESSIVE AGENT; MORPHINE; NEVIRAPINE; OPIATE RECEPTOR;

APOPTOSIS; BLOOD; BLOOD BRAIN BARRIER; BONE MARROW; BRAIN; BRAIN DYSFUNCTION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MIXED INFECTION; MORBIDITY; MORTALITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; REVIEW; SUBSTANCE ABUSE; TH1 CELL; TH2 CELL; VIROLOGY; VIRUS GENOME; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 84867629494     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212803306023     Document Type: Review

References (163)

1. 2010 Report on the global AIDS epidemic. UNAIDS/WHO 2010.
2. Bartlett JaFA. The guide to living with HIV infection. Sixth ed: A Johns Hopkins Press Health Book.
3. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986; 83(18): 7089-93.
4. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998; 280(5362): 427-31.
5. Fierer DS, Klotman ME. Kidney and central nervous system as reservoirs of HIV infection. Curr Opin HIV AIDS 2006; 1(2): 115-20.
6. Gunthard HF, Havlir DV, Fiscus S, et al. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001; 183(9): 1318-27.
7. McElrath MJ, Pruett JE, Cohn ZA. Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc Natl Acad Sci USA 1989; 86(2): 675-9.
8. Kilareski EM, Shah S, Nonnemacher MR, Wigdahl B. Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology 2009; 6: 118.
9. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387(6629): 183-8.
10. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53: 557-93.
11. Siliciano RF. What do we need to do to cure HIV infection. Top HIV Med 2010; 18(3): 104-8.
12. Palmer S, Josefsson L, Coffin JM. HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med 2011; 270(6): 550-60.
13. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008; 6(5): 388-400.
14. Kim WK, Corey S, Alvarez X, Williams K. Monocyte/macrophage traffic in HIV and SIV encephalitis. J Leukoc Biol 2003; 74(5): 650-6.
15. Burdo TH, Soulas C, Orzechowski K, et al. Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma. PLoS Pathog 2010; 6(4): e1000842.
16. McNamara LA, Collins KL. Hematopoietic stem/precursor cells as HIV reservoirs. Curr Opin HIV AIDS 2011; 6(1): 43-8.
17. Stanley SK, Kessler SW, Justement JS, et al. CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol 1992; 149(2): 689-97.
18. McGovern BH. The epidemiology, natural history and prevention of hepatitis B: implications of HIV coinfection. Antivir Ther 2007; 12 Suppl 3: H3-13.
19. Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009; 83(15): 7366-74.
20. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45(4): 529-38.
21. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13(17): 2436-41.
22. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(1 Suppl): S6-9.
23. Lee HC, Ko NY, Lee NY, Chang CM, Ko WC. Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection in Southern Taiwan, 2000-2005: upsurge in hepatitis C virus infections among injection drug users. J Formos Med Assoc 2008; 107(5): 404-11.
24. Nyirenda M, Beadsworth MB, Stephany P, et al. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect 2008; 57(1): 72-7.
25. Diop-Ndiaye H, Toure-Kane C, Etard JF, et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol 2008; 80(8): 1332-6.
26. III. KJWR. Do drugs of abuse impact on HIV disease? J Neuroimmunol 2004; 147: 6-8.
27. Drug-Associated HIV Transmission Continues in the United States. Centers for Disease Control and Prevention 2002.
28. Anthony IC AJ, Stephens B & Bell JE. The effets of illicit drugs on the HIV infected brain. Front Biosci 2008; 13: 1294-307.
29. D. DRV. Opiates as potential cofactors in progression of HIV-1 ifections to AIDS. J Neuroimmunol 1998; 83: 77-87.
30. Dhillon NK, Williams R, Peng F, et al. Cocaine-mediated enhancement of virus replication in macrophages: implications for human immunodeficiency virus-associated dementia. J Neurovirol 2007; 13(6): 483-95.
31. K. D. Regulation of hemopoiesis by bone marrow stromal cells and their products. Annu Rev Immunol 1990; 8: 111-37.
32. Allen TD, Dexter TM. The essential cells of the hemopoietic microenvironment. Exp Hematol 1984; 12(7): 517-21.
33. Liesveld JL, Abboud CN, Duerst RE, Ryan DH, Brennan JK, Lichtman MA. Characterization of human marrow stromal cells: role in progenitor cell binding and granulopoiesis. Blood 1989; 73(7): 1794-800.
34. Aboulafia DM, Mitsuyasu RT. Hematologic abnormalities in AIDS. Hematol Oncol Clin North Am 1991; 5(2): 195-214.
35. Davis BR, Zauli G. Effect of human immunodeficiency virus infection on haematopoiesis. Baillieres Clin Haematol 1995; 8(1): 113-30.
36. Scadden DT. ZLaGJ. Pathophysiology and management of HIVassociated hematologic disorders. Blood 1989; 74: 1455.
37. Re MC. FG, Zauli G. and La Placa M. Human immunodeficiency virus type 1 (HIV-1) and human progenitor cells. Arch Virol 1994; 137(1-2): 1-23.
38. Leiderman IZ. GM, Adelsberg BR and Siegal FP. A glycoprotein inhibitor of in vitro granulopoiesis associated with AIDS. Blood 1987; 70(5): 1267-72.
39. Scadden DT, Zeira M, Woon A, et al. Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood 1990; 76(2): 317-22.
40. Sugiura K. ON, Pahwa R., Kalyanaraman VS. and Pahwa S. Effect of human immunodeficiency virus-1 envelope glycoprotein on in vitro hematpoiesis of umbilical cord blood. Blood 1992; 80(6): 1463-9.
41. Zauli G. RM, Visani G., Furlini G and La Placa M. Inhibitory effect of HIV-1 envelope glycoproteins gp120 and gp160 on the in vitro growth of enriched (CD34+) hematopoietic progenitor cells. Arch Virol 1992; 122(3-4): 271-80.
42. Calenda V. GP, Delamarter JF and Chermann JC. Involvement of HIV nef protein in abnormal hematopoiesis in AIDS: in vitro study on bone marrow progenitor cells. Eur J Haematol 1994; 52(2): 103-7.
43. Folks TM, Kessler SW, Orenstein JM, Justement JS, Jaffe ES, Fauci AS. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 1988; 242(4880): 919-22.
44. Neal TF, Holland HK, Baum CM, et al. CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 1995; 86(5): 1749-56.
45. Varmus H. PT, Heasley S., Simon G and Bishop J. Cellular functions are required for the synthesis and integration of avian sarcoma virus-specific DNA. Cell 1977; 11: 307-19.
46. Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010; 16(4): 446-51.
47. Ercoli L, Sarmati L, Parisi SG, et al. Human immunodeficiency virus infection of human bone marrow stromal myoid cells. Scand J Infect Dis 1996; 28(4): 335-40.
48. Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 2011; 8(1): 54-61.
49. Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res 2011; 1399: 96-115.
50. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S. Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol 2000; 6 Suppl 1: S70-81.
51. Krmpotic-Nemanic J, Vinter I, Kelovizc Z, Marusic A. Postnatal changes of the clivus. Ann Anat 2005; 187(3): 277-80.
52. Ragin AB, Wu Y, Storey P, et al. Bone marrow diffusion measures correlate with dementia severity in HIV patients. AJNR Am J Neuroradiol 2006; 27(3): 589-92.
53. Thieblemont N, Weiss L, Sadeghi HM, Estcourt C, Haeffner-Cavaillon N. CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol 1995; 25(12): 3418-24.
54. Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. Lancet 1997; 349(9053): 692-5.
55. Koller M, Willheim M, Krugluger W, et al. Immunophenotyping of human bone marrow-derived macrophages. Scand J Immunol 1996; 43(6): 626-32.
56. Fagnoni FF, Oliviero B, Zibera C, et al. Circulating CD33+ large mononuclear cells contain three distinct populations with phenotype of putative antigen-presenting cells including myeloid dendritic cells and CD14+ monocytes with their CD16+ subset. Cytometry 2001; 45(2): 124-32.
57. Kim WK, Sun Y, Do H, et al. Monocyte heterogeneity underlying phenotypic changes in monocytes according to SIV disease stage. J Leukoc Biol 2010; 87(4): 557-67.
58. Fischer-Smith T, Croul S, Sverstiuk AE, et al. CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol 2001; 7(6): 528-41.
59. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro-and antiinflammatory stimuli. J Leukoc Biol 2000; 67(1): 97-103.
60. Gartner S. HIV infection and dementia. Science 2000; 287(5453): 602-4.
61. Dejean A, Lugassy C, Zafrani S, Tiollais P, Brechot C. Detection of hepatitis B virus DNA in pancreas, kidney and skin of two human carriers of the virus. J Gen Virol 1984; 65(Pt 3): 651-5.
62. Pontisso P, Poon MC, Tiollais P, Brechot C. Detection of hepatitis B virus DNA in mononuclear blood cells. Br Med J (Clin Res Ed) 1984; 288(6430): 1563-6.
63. Lie-Injo LE, Balasegaram M, Lopez CG, Herrera AR. Hepatitis B virus DNA in liver and white blood cells of patients with hepatoma. DNA 1983; 2(4): 301-8.
64. Yoffe B, Noonan CA, Melnick JL, Hollinger FB. Hepatitis B virus DNA in mononuclear cells and analysis of cell subsets for the presence of replicative intermediates of viral DNA. J Infect Dis 1986; 153(3): 471-7.
65. Blum HE, Stowring L, Figus A, Montgomery CK, Haase AT, Vyas GN. Detection of hepatitis B virus DNA in hepatocytes, bile duct epithelium, and vascular elements by in situ hybridization. Proc Natl Acad Sci USA 1983; 80(21): 6685-8.
66. Romet-Lemonne JL, McLane MF, Elfassi E, Haseltine WA, Azocar J, Essex M. Hepatitis B virus infection in cultured human lymphoblastoid cells. Science 1983; 221(4611): 667-9.
67. Laure F, Zagury D, Saimot AG, Gallo RC, Hahn BH, Brechot C. Hepatitis B virus DNA sequences in lymphoid cells from patients with AIDS and AIDS-related complex. Science 1985; 229(4713): 561-3.
68. Noonan CA, Yoffe B, Mansell PW, Melnick JL, Hollinger FB. Extrachromosomal sequences of hepatitis B virus DNA in peripheral blood mononuclear cells of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986; 83(15): 5698-702.
69. Hoar DI, Bowen T, Matheson D, Poon MC. Hepatitis B virus DNA is enriched in polymorphonuclear leukocytes. Blood 1985; 66(6): 1251-3.
70. Michalak TI. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol Rev 2000; 174: 98-111.
71. Zeldis JB, Dienstag JL, Gale RP. Aplastic anemia and non-A, non-B hepatitis. Am J Med 1983; 74(1): 64-8.
72. Zeldis JB, Mugishima H, Steinberg HN, Nir E, Gale RP. In vitro hepatitis B virus infection of human bone marrow cells. J Clin Invest 1986; 78(2): 411-7.
73. Zeldis JB, Farraye FA, Steinberg HN. In vitro hepatitis B virus suppression of erythropoiesis is dependent on the multiplicity of infection and is reversible with anti-HBs antibodies. Hepatology 1988; 8(4): 755-9.
74. Hwang YY, Liang RH. Hepatitis C in haematological patients. Hepat Res Treat 2010; 2010: 961359.
75. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006; 23(8): 1055-65.
76. Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339(11): 746-54.
77. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100(10): 3457-69.
78. Kottilil S, Yan MY, Reitano KN, et al. Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology 2009; 50(1): 34-45.
79. You J, Sriplung H, Geater A, et al. Effect of viral load on Tlymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol 2008; 14(7): 1112-9.
80. Mizukoshi E, Sidney J, Livingston B, et al. Cellular immune responses to the hepatitis B virus polymerase. J Immunol 2004; 173(9): 5863-71.
81. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102(5): 968-75.
82. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33(4): 963-71.
83. Thio CL. Hepatitis B in the human immunodeficiency virusinfected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003; 23(2): 125-36.
84. Thio CL, Seaberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360(9349): 1921-6.
85. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19(6): 593-601.
86. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85(1): 303-15.
87. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163(5): 1138-40.
88. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163(3): 454-9.
89. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29(4): 1306-10.
90. Clifford GM, Rickenbach M, Polesel J, et al. Influence of HIVrelated immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22(16): 2135-41.
91. Fang JW, Wright TL, Lau JY. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet 1993; 342(8880): 1175.
92. Guirgis BS, Abbas RO, Azzazy HM. Hepatitis B virus genotyping: current methods and clinical implications. Int J Infect Dis 2010; 14(11): e941-53.
93. Martin CM, Welge JA, Blackard JT. Hepatitis B virus (HBV) X gene diversity and evidence of recombination in HBV/HIV coinfected persons. J Med Virol 2011; 83(7): 1142-50.
94. Lacombe K, Massari V, Girard PM, et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 2006; 20(3): 419-27.
95. Gunther S, Baginski S, Kissel H, et al. Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology 1996; 24(4): 751-8.
96. Preikschat P, Gunther S, Reinhold S, et al. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology 2002; 35(2): 466-77.
97. Gunther S, Piwon N, Jung A, Iwanska A, Schmitz H, Will H. Enhanced replication contributes to enrichment of hepatitis B virus with a deletion in the core gene. Virology 2000; 273(2): 286-99.
98. Revill PA, Littlejohn M, Ayres A, et al. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS 2007; 21(13): 1701-10.
99. Thomas DL, Astemborski J, Vlahov D, et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000; 181(3): 844-51.
100. Matthews-Greer JM, Caldito GC, Adley SD, et al. Comparison of hepatitis C viral loads in patients with or without human immunodeficiency virus. Clin Diagn Lab Immunol 2001; 8(4): 690-4.
101. Wang X, Zhang T, Ho WZ. Opioids and HIV/HCV infection. J Neuroimmune Pharmacol 2011; 6(4): 477-89.
102. Capa L, Soriano V, Garcia-Samaniego J, et al. Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus. J Med Virol 2007; 79(5): 503-10.
103. Irshad M, Ansari MA, Singh A, et al. HCV-genotypes: a review on their origin, global status, assay system, pathogenecity and response to treatment. Hepatogastroenterology 2010; 57(104): 1529-38.
104. Lopez-Labrador FX, Dove L, Hui CK, et al. Trends for genetic variation of Hepatitis C Virus quasispecies in Human Immunodeficiency virus-1 coinfected patients. Virus Res 2007; 130(1-2): 285-91.
105. Sherman KE, Andreatta C, O'Brien J, Gutierrez A, Harris R. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain. Hepatology 1996; 23(4): 688-94.
106. MacDonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol 2008; 14(11): 1657-63.
107. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164(21): 2349-54.
108. McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol 2006; 24(31): 5005-9.
109. Murillas J, Del Rio M, Riera M, et al. Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. Eur J Intern Med 2005; 16(2): 113-5.
110. McGlynn KA, W.T. L. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011; 15(2): 223-43.
111. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Populationbased risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26(9): 2183-91.
112. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54(2): 463-71.
113. Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. Hepatobiliary cancers in persons with HIV/AIDS in the United States. Infect Agent Cancer 2012; 7(Suppl 1): 25.
114. Sauleda S, Martorell M, Esteban JI, et al. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade. Haemophilia 2006; 12(3): 228-36.
115. Sterling RK, Orenstein R, Contos MJ, et al. The spectrum of hepatitis C virus (HCV) in human immunodeficiency virus (HIV) coinfection: Stratification by stage and immune function. Gastroenterology 2001; 120(5): A553.
116. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166(15): 1632-41.
117. Maida I, Soriano V, Castellares C, et al. Liver fibrosis in HIVinfected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. HIV clinical trials 2006; 7(5): 246-50.
118. Mallet VO, Dhalluin-Venier V, Verkarre V, et al. Reversibility of cirrhosis in HIV/HBV coinfection. Antivir Ther 2007; 12(2): 279-83.
119. Tuma P, Medrano J, Resino S, et al. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther 2010; 15(6): 881-6.
120. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18(5): 767-74.
121. Jones M, Nunez M. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management. Curr Opin HIV AIDS 2011; 6(6): 546-52.
122. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34(2): 283-7.
123. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44(1): 47-55.
124. Tural C, Fuster D, Tor J, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003; 10(2): 118-25.
125. Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol 1998; 83(1-2): 77-87.
126. Arora PK, Fride E, Petitto J, Waggie K, Skolnick P. Morphineinduced immune alterations in vivo. Cell Immunol 1990; 126(2): 343-53.
127. Bryant HU, Bernton EW, Holaday JW. Immunosuppressive effects of chronic morphine treatment in mice. Life Sci 1987; 41(14): 1731-8.
128. Steidl U, Bork S, Schaub S, et al. Primary human CD34+ hematopoietic stem and progenitor cells express functionally active receptors of neuromediators. Blood 2004; 104(1): 81-8.
129. Rozenfeld-Granot G, Toren A, Amariglio N, et al. MAP kinase activation by mu opioid receptor in cord blood CD34(+)CD38(-) cells. Exp Hematol 2002; 30(5): 473-80.
130. Sei Y, Yoshimoto K, McIntyre T, Skolnick P, Arora PK. Morphine-induced thymic hypoplasia is glucocorticoid-dependent. J Immunol 1991; 146(1): 194-8.
131. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383(6603): 787-93.
132. Roy S, Wang J, Charboneau R, Loh HH, Barke RA. Morphine induces CD4+ T cell IL-4 expression through an adenylyl cyclase mechanism independent of the protein kinase A pathway. J Immunol 2005; 175(10): 6361-7.
133. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 2006; 1(3): 280-95.
134. Weber JE, Larkin GL, Boe CT, et al. Effect of cocaine use on bone marrow-mediated erythropoiesis. Acad Emerg Med 2003; 10(7): 705-8.
135. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003; 16(2): 209-19.
136. Baldwin GC, Roth MD, Tashkin DP. Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J Neuroimmunol 1998; 83(1-2): 133-8.
137. Roth MD, Tashkin DP, Choi R, Jamieson BD, Zack JA, Baldwin GC. Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis 2002; 185(5): 701-5.
138. Rafie C, Campa A, Smith S, Huffman F, Newman F, Baum MK. Cocaine reduces thymic endocrine function: Another mechanism for accelerated HIV disease progression. AIDS Res Hum Retroviruses 2011; 27(8): 815-22.
139. Tegeder I, Geisslinger G. Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indications. Pharmacol Rev 2004; 56(3): 351-69.
140. Banerjee A, Strazza M, Wigdahl B, Pirrone V, Meucci O, Nonnemacher MR. Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neurovirol 2011; 17(4): 291-302.
141. Chuang LF, Killam KF, Jr., Chuang RY. Increased replication of simian immunodeficiency virus in CEM x174 cells by morphine sulfate. Biochem Biophys Res Commun 1993; 195(3): 1165-73.
142. Hao YS, Li PF, Zhang FX, Huang DA, Liu XH, Li G. Morphine alleviates early stages of apoptosis in cultured CEM x174 cells infected with simian immunodeficiency virus. Cell Biol Int 2003; 27(9): 719-25.
143. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH, Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 1990; 4(9): 869-73.
144. Peterson PK, Gekker G, Hu S, et al. Morphine amplifies HIV-1 expression in chronically infected promonocytes cocultured with human brain cells. J Neuroimmunol 1994; 50(2): 167-75.
145. Bokhari SM, Yao H, Bethel-Brown C, et al. Morphine enhances Tat-induced activation in murine microglia. J Neurovirol 2009; 15: 219-28.
146. Kumar R, Torres C, Yamamura Y, et al. Modulation by morphine of viral set point in rhesus macaques infected with simian immunodeficiency virus and simian-human immunodeficiency virus. J Virol 2004; 78(20): 11425-8.
147. Ou DW, Shen ML, Luo YD. Effects of cocaine on the immune system of Balb/C mice. Clin Immunol Immunopathol 1989; 52(2): 305-12.
148. Maurice T, Martin-Fardon R, Romieu P, Matsumoto RR. Sigma(1) (sigma(1)) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 2002; 26(4): 499-527.
149. Fox L, Alford M, Achim C, Mallory M, Masliah E. Neurodegeneration of somatostatin-immunoreactive neurons in HIV encephalitis. J Neuropathol Exp Neurol 1997; 56(4): 360-8.
150. Petito CK, Roberts B, Cantando JD, Rabinstein A, Duncan R. Hippocampal injury and alterations in neuronal chemokine coreceptor expression in patients with AIDS. J Neuropathol Exp Neurol 2001; 60(4): 377-85.
151. Masliah E, Ge N, Achim CL, Hansen LA, Wiley CA. Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol 1992; 51(6): 585-93.
152. Kogan M, Rappaport J. HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 2011; 8: 25.
153. Venkatesan A, Nath A, Ming GL, Song H. Adult hippocampal neurogenesis: regulation by HIV and drugs of abuse. Cell Mol Life Sci 2007; 64(16): 2120-32.
154. Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crackcocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr 2009; 50(1): 93-9.
155. Cook JA, Burke-Miller JK, Cohen MH, et al. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS 2008; 22(11): 1355-63.
156. Duncan R, Shapshak P, Page JB, Chiappelli F, McCoy CB, Messiah SE. Crack cocaine: effect modifier of RNA viral load and CD4 count in HIV infected African American women. Front Biosci 2007; 12: 1488-95.
157. Zamani S, Radfar R, Nematollahi P, et al. Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited through peer-driven sampling in Iran. Int J Drug Policy 2010; 21(6): 493-500.
158. Bao YP, Liu ZM. Systematic review of HIV and HCV infection among drug users in China. Int J STD AIDS 2009; 20(6): 399-405.
159. Mahanta J, Borkakoty B, Das HK, Chelleng PK. The risk of HIV and HCV infections among injection drug users in northeast India. AIDS Care 2009; 21(11): 1420-4.
160. Marchesini AM, Pra-Baldi ZP, Mesquita F, Bueno R, Buchalla CM. Hepatitis B and C among injecting drug users living with HIV in Sao Paulo, Brazil. Rev Saude Publica 2007; 41 Suppl 2: 57-63.
161. Sanvisens A, Fuster D, Serra I, et al. Estimated liver fibrosis and its impact on all-cause mortality of HCV-monoinfected and HCV/HIV-coinfected drug users. Curr HIV Res 2011; 9(4): 256-62.
162. Graham CS, Wells A, Edwards EM, et al. Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection. J Infect Dis 2007; 195(6): 847-56.
163. Graham CS, Wells A, Liu T, et al. Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS 2005; 19(8): 767-73.